SANDERS FORCES NOVO NORDISK CEO TO TESTIFY

Sen. Bernie Sanders has successfully persuaded Novo Nordisk CEO Lars Jørgensen to testify before the Senate HELP Committee regarding the high prices of Ozempic and Wegovy in the US. Scheduled for early September, this testimony comes after Sanders’s persistent efforts, including a threat to subpoena the company, to address the significant price disparities these drugs have between the US and other countries. For example, Ozempic costs $969 per month in the US compared to $155 in Canada. A Yale study noted these drugs could be manufactured for under $5 each. Novo Nordisk attributes the high US prices to systemic issues within the American health system, including middlemen. However, the HELP committee’s May report warns that the high costs could severely strain the US healthcare system, emphasizing the urgent need for explanation and potential price adjustments. (Ars Technica)

HOUSE BILL TO HALT DOD FUNDS FOR CHINA TIES

Last week, the U.S. House of Representatives passed a defense policy bill with a provision that would stop the Department of Defense (DOD) from funding U.S. universities that collaborate on research with China. This proposal is part of ongoing efforts by congressional Republicans to prevent the transfer of U.S.-funded technology to China. While science advocates oppose this measure, they are cautiously optimistic it will be removed during Senate negotiations on the National Defense Authorization Act (NDAA). The bill also targets collaborations with Russia, Iran, and North Korea, restricting DOD-funded universities from associating with institutions or individuals from these countries. Representative Jim Banks, who introduced the provision, emphasized the need to protect American innovation from foreign exploitation. However, the White House and some Democrats argue that such restrictions could hinder the U.S. in maintaining its technological edge by limiting collaborations with global talents. The bill passed the House mostly along party lines and awaits further debate in the Senate. (Science)

If you’re enjoying the Daily Dose, sign up for the Daily Dose Newsletter and get the morning’s best science news from around the web delivered straight to your inbox? It’s easy like Sunday morning.

JIANG XUEFENG REVOLUTIONIZES SULFUR CHEMISTRY IN CHINA

Since 2008, Jiang Xuefeng has spearheaded a transformative approach to sulfur chemistry in China, aiming to revamp sulfur’s image from merely a problematic chemical to a pivotal element in technology and medicine. He developed “3S sulfur chemistry,” which focuses on creating stable, sustainable, and less odorous sulfur applications. This innovation has led to over 100 patents and numerous collaborations across various industries, significantly reducing sulfur’s traditionally pungent smell and increasing its utility. Jiang’s work extends beyond the lab. He has initiated a project in Hainan to address marine plastic pollution using chemical degradation methods that offer a more environmentally friendly solution than traditional techniques. His research is supported by his studies in the U.S. and his academic roles in China, emphasizing the need to innovate and overcome technical challenges in sulfur usage. Despite early financial hurdles, Jiang’s dedication to advancing sulfur chemistry has garnered significant recognition and funding, enabling him to pursue further cutting-edge projects. (Sixth Tone)

WEGOVY HELPS WENATCHEE WOMAN BEAT ARTHRITIS, BP WOES

Lesa Walton, a 57-year-old from Wenatchee, Washington, found significant relief from her rheumatoid arthritis and high blood pressure after losing over 50 pounds using the obesity drug Wegovy, prescribed by Dr. Stefie Deeds. This case exemplifies the “obesity first” approach, where obesity is targeted with specific medications, leading to improvements in related chronic diseases. However, this method is controversial; while some celebrate the unexpected benefits of obesity drugs, others caution against their high cost and lack of rigorous study evidence supporting broader health benefits. Critics like Dr. Gordon Guyatt advocate for tested, inexpensive treatments for conditions accompanying obesity, rather than directly treating obesity with expensive drugs. The debate extends to the effectiveness of these drugs in treating conditions like inflammation independently of weight loss, with ongoing studies exploring their potential in addressing various medical conditions beyond obesity. This evolving field highlights differing medical philosophies on whether to prioritize obesity treatment to potentially resolve related conditions. (New York Times)

JUNE IN JAPAN: RAINY SEASON, HIGH HUMIDITY, NO HOLIDAYS

June in Japan presents significant challenges that can make it arguably the worst month of the year. The primary obstacle is the rainy season, which spans from Aomori in the north to Okinawa in the south, excluding Hokkaido. This period, lasting six to eight weeks, brings high humidity and frequent rain due to the clash of cold and warm air masses. Tokyo, for instance, sees average humidity levels around 80% in June. This damp environment fosters the growth of mold and the proliferation of mosquitoes, which thrive in warm, stagnant water. Adding to the discomfort, there are no public holidays in June, creating a long stretch between the end of Golden Week in early May and Mountain Day in August without any official breaks. Despite these adversities, there are positives such as the beautiful ajisai (hydrangea) season and relatively moderate temperatures compared to the peak summer months. Preparations like having dehumidifiers, using insect repellents, and carrying rain gear can help mitigate some of June’s challenges. (Japan Today)

BRAIN STIMULATION DEVICE MAY EASE LOVE TRAUMA SYNDROME

Research on love trauma syndrome (LTS), the emotional pain caused by romantic breakups, suggests a potential remedy using a device that stimulates the brain. In a study involving 36 volunteers experiencing LTS, participants used transcranial direct-current stimulation (tDCS) headsets. These headsets targeted either the dorsolateral prefrontal cortex (DLPFC) or the ventrolateral prefrontal cortex (VLPFC) for 20 minutes, twice a day over five days. The study found that stimulation of the DLPFC was particularly effective in reducing symptoms of LTS, depression, and anxiety compared to the VLPFC and a control group with the headset off. Results persisted for a month post-treatment. Published in the Journal of Psychiatric Research, this study points to the promising use of tDCS as a supplementary treatment to traditional methods like cognitive-behavioral therapy, especially for patients where conventional treatments are ineffective. Further research with larger trials is needed to validate these findings. (The Guardian)

Thanks for reading. Let’s be careful out there.

WORDS: The Biology Guy.